Richard D. Carvajal

TL;DR: Vemurafenib is highly active in BRAF-mutant melanoma brain metastases but has limited activity in patients with poor performance status, and preliminary data indicate that co-occurring or secondary alterations in the phosphatidylinositol 3-kinase-AKT pathway are involved in resistance to RAF inhibition, thus providing a rationale for dual MAPK and PI3K-AKt pathway inhibition in this patient population.

TL;DR: AZD5438 was generally well tolerated in a weekly dosing schedule, but not in continuous schedules; however, when dosed continuously, 40 mg four times daily was considered intolerable, and all studies were terminated prematurely.

TL;DR: In these studies, selected patients with KIT-mutated melanoma were shown to be responsive to therapy with K IT inhibition, especially patients with L576P and K642E mutations, which has led to the incorporation of K IT-targeted therapy in the National Comprehensive Cancer Network guidelines for systemic therapy for metastatic or unresectable melanoma.

TL;DR: Ieramilimab was well tolerated as monotherapy and in combination with spartalizumab, and the toxicity profile of ieramILimab in combination in comparison to that of spartALIZumab alone.

TL;DR: Building on the success of autologous cell transfer in hematologic malignancies, designing chimeric antigen receptors that target antigens that are over-expressed in sarcoma provides a great deal of optimism.